GreatPoint Ventures Invests In Leading Gene Therapy Delivery Platform
ATLANTA - March 1, 2019 - PRLog -- GreatPoint Ventures, a leading San Francisco based venture capital firm, announced the closing of an investment in Guide Therapeutics, Inc. (GuideRx), a developer of lipid nanoparticles (LNPs) for delivery of therapeutics for gene therapy. GuideRx was organized around the work of Professor James E. Dahlman, formerly of the labs of pioneers in gene therapy including Robert Langer of MIT and Feng Zhang of the Broad Institute. Professor Dahlman is faculty in the Department of Biomedical Engineering at Georgia Institute of Technology and Emory School of Medicine. Dr. Dahlman was recently recognized by MIT Technology Review as one of the Top 35 Scientists under 35 for this work. Based upon the work of Dr. Dahlman, GuideRx is able to screen more than 30,000 LNPs in vivo per year to develop LNPs with high affinity for non-liver cell types and low affinity for non-target tissues employing its unique patented platform technology. GuideRx's technology has identified nanoparticles that have shown functional delivery to non-liver cell types, greatly extending the potential for treating genetic disease.
Tom Saylor, CEO of GuideRx said, "The investment by GreatPoint Ventures provides GuideRx with an opportunity to accelerate its development of therapeutic candidates for treatment of genetic diseases. The ability to deliver to non-liver tissue has become a key bottleneck in the wider application of gene therapies. In partnership with GreatPoint Ventures, GuideRx not only expects to shorten drug development timescales by side-stepping in vitro reseach but to offer safer ways to treat genetic disease."
Andrew Perlman, Managing Partner at GreatPoint Ventures stated, "GreatPoint has been fortunate to seal a partnership with GuideRx, which promises to be a major player in the next generation of gene therapy utilizing its proprietary ability to develop drugs that can selectively target non-liver cell types. We are confident that Guide will be one of the top players in the rapidly emerging field of gene therapy."
Guide Therapeutics, Inc.
Page Updated Last on: Mar 01, 2019